Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K. von Birgelen C, et al. Among authors: van houwelingen gk. Lancet. 2014 Feb 1;383(9915):413-23. doi: 10.1016/S0140-6736(13)62037-1. Epub 2013 Oct 31. Lancet. 2014. PMID: 24183564 Clinical Trial.
Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, de Man FH, Louwerenburg JH, van Houwelingen GK, Linssen GC, Doggen CJ, Basalus MW, von Birgelen C. Sen H, et al. Among authors: van houwelingen gk. Catheter Cardiovasc Interv. 2015 Jan 1;85(1):74-81. doi: 10.1002/ccd.25464. Epub 2014 Mar 14. Catheter Cardiovasc Interv. 2015. PMID: 24585502 Clinical Trial.
Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population.
Kok MM, von Birgelen C, Sattar N, Zocca P, Löwik MM, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Kant GD, Doelman C, Tjon Joe Gin M, Stoel MG, van Houwelingen G, Linssen GCM, IJzerman MJ, Doggen CJM, van der Heijden LC. Kok MM, et al. EuroIntervention. 2018 Oct 12;14(9):e1049-e1056. doi: 10.4244/EIJ-D-17-01067. EuroIntervention. 2018. PMID: 29313817 Free article.
Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial.
Kok MM, Zocca P, Buiten RA, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Stoel MG, van Houwelingen G, Linssen GCM, Doggen CJM, von Birgelen C. Kok MM, et al. EuroIntervention. 2018 Oct 20;14(8):915-923. doi: 10.4244/EIJ-D-18-00336. EuroIntervention. 2018. PMID: 29790480 Free article. Clinical Trial.
The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy.
Heestermans T, van 't Hof AW, ten Berg JM, van Werkum JW, Boersma E, Mosterd A, Stella PR, van Zoelen AB, Gosselink AT, Kochman W, Dill T, Koopmans PC, van Houwelingen G, Zijlstra F, Hamm C. Heestermans T, et al. Am Heart J. 2010 Dec;160(6):1079-84. doi: 10.1016/j.ahj.2010.08.039. Am Heart J. 2010. PMID: 21146661 Clinical Trial.
Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: correlates of reperfusion before primary PCI.
Heestermans T, Suryapranata H, ten Berg JM, Mosterd A, Gosselink AT, Kochman W, Dill T, van Houwelingen G, Kolkman E, van Werkum JW, Zijlstra F, Hamm C, van 't Hof AW. Heestermans T, et al. J Electrocardiol. 2011 Jan-Feb;44(1):42-8. doi: 10.1016/j.jelectrocard.2010.09.010. J Electrocardiol. 2011. PMID: 21168000 Clinical Trial.
Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.
Van't Hof AW, Ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Van't Hof AW, et al. Lancet. 2008 Aug 16;372(9638):537-46. doi: 10.1016/S0140-6736(08)61235-0. Lancet. 2008. PMID: 18707985 Clinical Trial.
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Heestermans AA, Van Werkum JW, Hamm C, Dill T, Gosselink AT, De Boer MJ, Van Houwelingen G, Hoorntje JC, Koopmans PC, Ten Berg JM, Van 't Hof AW. Heestermans AA, et al. J Thromb Haemost. 2009 Oct;7(10):1612-8. doi: 10.1111/j.1538-7836.2009.03573.x. Epub 2009 Aug 11. J Thromb Haemost. 2009. PMID: 19682233 Free article. Clinical Trial.
33 results